# Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

> **NCT04251065** · PHASE2 · TERMINATED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 8 (actual)

## Conditions studied

- Refractory T-Cell Lymphoma
- Relapsed T-Cell Lymphoma

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT04251065
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-03
- **Primary completion:** 2021-12-22
- **Final completion:** 2022-11-23
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The enrolment was prematurely terminated after the planned monitoring of the first 5 patients because of an unacceptable level of relevant toxicities, according to statistical stopping rules and the DSMB recommendation.
- **Last updated:** 2025-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04251065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04251065, "Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04251065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*